ArticleProceedings of the National Academy of Sciences of the United States of America2017
Immune protection against reinfection with nonprimate hepacivirus.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Lack of evidence for arthropod or vertical transmission of Hepacivirus bovis in a persistently infected dairy herd.Archives of virology · 2026Article
- Chronic hepatitis in horses with persistent equine hepacivirus infection.Equine veterinary journal · 2026Article
- First Detection and Phylogenetic Analysis of Equine Hepacivirus (EqHV) in Iran.Veterinary medicine and science · 2026Article
- First detection of equine hepacivirus RNA in Stomoxys calcitrans (Diptera, Muscidae) in eastern Austria.BMC veterinary research · 2025Article
- Article
- Mouse Liver-Expressed Shiftless Is an Evolutionarily Conserved Antiviral Effector Restricting Human and Murine Hepaciviruses.Microbiology spectrum · 2023Article
- Description of an Equine Hepacivirus Cluster in a Horse Stable in Italy.Transboundary and emerging diseases · 2023Article
- European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe.Journal of veterinary internal medicine · 2022Article
- Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response.Microbiology spectrum · 2022Article
- Equine Hepacivirus: A Systematic Review and a Meta-Analysis of Serological and Biomolecular Prevalence and a Phylogenetic Update.Animals : an open access journal from MDPI · 2022Review
- Article
- Experimental cross-species infection of donkeys with equine hepacivirus and analysis of host immune signatures.One health outlook · 2022Article
- Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.Virus evolution · 2022Article
- Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.Hepatology (Baltimore, Md.) · 2021Article
- Review
- Liver-expressedScience advances · 2020Article
- First report of equine parvovirus-hepatitis-associated Theiler's disease in Europe.Equine veterinary journal · 2020Article
- Animal Models of Hepatitis C Virus Infection.Cold Spring Harbor perspectives in medicine · 2020Review
- Article
- Structure-function analysis of the equine hepacivirus 5' untranslated region highlights the conservation of translational mechanisms across the hepaciviruses.The Journal of general virology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) displays a restricted host species tropism and only humans and chimpanzees are susceptible to infection. A robust immunocompetent animal model is still lacking, hampering mechanistic analysis of virus pathogenesis, immune control, and prophylactic vaccine development. The closest homolog of HCV is the equine nonprimate hepacivirus (NPHV), which shares similar features with HCV and thus represents an animal model to study hepacivirus infections in their natural hosts. We aimed to dissect equine immune responses after experimental NPHV infection and conducted challenge experiments to investigate immune protection against secondary NPHV infections. Horses were i.v. injected with NPHV containing plasma. Flow cytometric analysis was used to monitor immune cell frequencies and activation status. All infected horses became viremic after 1 or 2 wk and viremia could be detected in two horses for several weeks followed by a delayed seroconversion and viral clearance. Histopathological examinations of liver biopsies revealed mild, periportally accentuated infiltrations of lymphocytes, macrophages, and plasma cells with some horses displaying subclinical signs of hepatitis. Following viral challenge, an activation of equine immune responses was observed. Importantly, after a primary NPHV infection, horses were protected against rechallenge with the homologous as well as a distinct isolate with only minute amounts of circulating virus being detectable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.